Evidence map›Paper›PMID 26334502›Full record

ArticlePharmaceutical research2016

A Promising Emodin-Loaded Poly (Lactic-Co-Glycolic Acid)-d-α-Tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles for Liver Cancer Therapy.

Hongyan Liu, Meng Gao, Hong Xu, Xin Guan, Li Lv, Sa Deng, Chenghong Zhang, Yan Tian

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Mechanism of Emodin in the Treatment of Rheumatoid Arthritis.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hongyan LiuCollege of Pharmacy, Dalian Medical University, Dalian, 116044, China.
Meng GaoCollege of Pharmacy, Dalian Medical University, Dalian, 116044, China.
Hong XuCollege of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Xin GuanCollege of Pharmacy, Dalian Medical University, Dalian, 116044, China.
Li LvCollege of Pharmacy, Dalian Medical University, Dalian, 116044, China.
Sa DengCollege of Pharmacy, Dalian Medical University, Dalian, 116044, China.
Chenghong ZhangCollege of Basic Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Yan TianCollege of Pharmacy, Dalian Medical University, Dalian, 116044, China. tiany2004@126.com.
Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEmodin (EMO) has multi-targets and multi-way antitumor effect, which was limited by the instability and poor solubility of EMO. The aim of this study was to formulate EMO-loaded poly (lactide-co-glycolide)-d-α-tocopheryl polyethylene glycol 1000 succinate (PLGA-TPGS) nanoparticles (EPTN) to increase the liver targeting of EMO for cancer therapy.

methodsEMO/coumarin-6-loaded PLGA-TPGS nanoparticles (ECPTN) and EMO-loaded PLGA nanoparticles (EPN) were also prepared as comparison. The cellular uptake of ECPTN by HepG2 and HCa-F cells was investigated using Confocal laser scanning microscopy. The apoptosis of HepG2 cells handled with EPTN was assayed by flow cytometry. The liver targeting property of ECPTN in mice was evaluated using the drug concentration determined by RP-HPLC and the freezing slices were investigated via fluorescence inversion microscopy. The blood samples were obtained from vein intubation to illustrate the pharmacokinetics process of EPTN. The tumor-bearing mice model was established to elucidate the in vivo therapeutic effect of EPTN.

resultsThe results demonstrated that ECPTN could be internalized by HepG2 and HCa-F cells respectively. The ratio of apoptosis cells was increased after dealing with EPTN. The detection indexes of drug concentration and fluorescence inversion microscopy images indicated ECPTN had an excellent effect on liver targeting property than EMO solutions (EMS). The pharmacokinetics process of EPTN showed obvious sustained-release effect than EMS. Compared with EPN, the in vivo antitumor activity of EPTN against tumor cells were better.

conclusionsIn conclusion, EPTN could be used in the treatment of liver cancer acted as a kind of promising intravenous dosage forms.

Indexed as

alpha-TocopherolAnimalsAntineoplastic AgentsApoptosisCell Line, TumorDelayed-Action PreparationsDrug Delivery SystemsEmodinHumansLactic AcidLiver NeoplasmsMiceNanoparticlesParticle SizePolyethylene GlycolsPolyglycolic Acidalpha-TocopherolAntineoplastic AgentsDelayed-Action PreparationsEmodinLactic AcidPolyethylene GlycolsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerEmodinliver cancerliver targeting propertynanoparticlesPLGA-TPGS

Identifiers

PMID26334502
OpenAlexW2172140039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.